首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

2135000

微量殘存疾病（MRD）流行病學市場：策略性洞察與預測（2026-2031 年）

Minimal Residual Disease Epidemiology Market - Strategic Insights and Forecasts (2026-2031)

出版日期: 2026年09月14日 | 出版商:

Knowledge Sourcing Intelligence | 英文 132 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

隨著精準癌症治療和分子診斷技術的進步，癌症治療格局發生變革，微量殘存疾病（MRD）的流行病學在全球備受關注。 MRD是指治療後殘留在患者體內的少量癌細胞，這些癌細胞通常無法透過常規診斷方法檢測到。 MRD的流行病學分析主要關注骨髓惡性腫瘤和某些固體癌的盛行率、發生率、確診患者族群、治療模式、復發率以及長期臨床結局。 MRD作為預後和預測性生物標記的日益普及，推動了對全面流行病學數據的需求不斷成長，以支持臨床研究、醫療保健規劃、藥物研發和商業化策略。

隨著白血病、淋巴瘤、多發性骨髓瘤和其他血液系統癌症在全球範圍內造成的疾病負擔日益加重，對精準的經絡相關疾病（MRD）流行病學研究的需求也日益成長。製藥公司、診斷試劑開發商、醫療服務提供者和監管機構正擴大利用患者群體分析來指導臨床試驗指南、評估治療效果、識別未滿足的需求並預測未來對MRD檢測和標靶治療的需求。次世代定序（NGS）、聚合酵素鏈鎖反應（PCR）、流式細胞技術和液態生物檢體技術的日益融合，進一步加強了疾病監測和流行病學研究。

對精準醫療、個人化癌症療法和生物標記驅動療法的投資不斷增加，正在加速關鍵醫療市場中綜合性微小殘留疾病（MRD）流行病學資料庫的建設。癌症登記、電子健康記錄、真實世界數據（RWE）平台和人工智慧數據分析技術的進步，預計將在預測期內顯著提高流行病學預測的品質和準確性。

市場促進因素

骨髓惡性腫瘤發生率增加

白血病、淋巴瘤、多發性骨髓瘤和其他血液癌症的日益流行，促使人們越來越需要進行詳細的 MRD 流行病學研究，以支持疾病監測和治療計劃。
隨著患者數量的增加，流行病學分析的需求變得越來越重要。

精準醫療的廣泛應用

在個人化治療策略中，越來越依賴 MRD 評估來選擇治療方案、預測復發和長期疾病管理。
向生物標記驅動的腫瘤學轉變持續推動流行病學研究。

分子診斷技術的進展

NGS、PCR、流式細胞技術和液態生物檢體等技術提高了 MRD 檢測的靈敏度，從而可以更準確地評估患者群體。
技術進步不斷提高流行病學數據的品質。

擴大臨床試驗活動

MRD終點指標正擴大被納入腫瘤臨床試驗中，以評估治療效果並加速藥物研發。
隨著基於生物標記的臨床研究的擴展，對流行病學資料集的需求也在增加。

擴展真實世界證據

醫療機構擴大利用患者登記、電子健康記錄和真實世界證據來改善疾病監測和流行病學預測。
先進的分析技術正在不斷改善醫療保健領域的決策。

市場限制因素

MRD評估缺乏標準化

調查方法、報告標準和臨床實踐的差異會影響醫療保健系統流行病學數據的一致性。
為實現全球和諧所做的努力至今仍在繼續。

先進診斷技術高成本

先進的分子檢測平台需要大量投資，這限制了它們在某些醫療機構中的廣泛應用。
不同地區獲得檢測的機會仍有差異。

新興市場數據可用性有限

開發中國家癌症登記不完整、醫療保健報告系統不一致，可能會限制高品質流行病學資訊的取得。
預計隨著醫療基礎設施的改善，這些限制將在未來逐漸消失。

微量殘存疾病（MRD）概述
- 定義和臨床意義
- MRD在疾病監測中的作用
骨髓惡性腫瘤中的微小殘留病灶
- 急性淋巴性白血病（ALL）
- 急性骨髓性白血病（AML）
- 慢性淋巴性白血病（CLL）
- 多發性骨髓瘤
- 非何傑金氏淋巴瘤（NHL）
- 其他血液疾病
全球發生率和盛行率（從疾病特異性微小殘留疾病的角度）
- 按適應症分類的發生率
- 按適應症分類的盛行率
- 與微小殘留病灶陽性相關的復發率
患者分層和風險分類
- MRD陽性組和MRD陰性組的結果
- 微小殘留病灶的預後價值
MRD檢測滲透率和採用率
臨床試驗和真實世界中微小殘留疾病資料的變異性

第3章：微量殘存疾病流行病學報告的趨勢

市場促進因素
- 擴大微小殘留病灶作為預後生物標記的應用
- 精準腫瘤學引入範圍的擴大
- 先進分子診斷技術的廣泛應用
市場限制因素
- MRD檢測方法的標準化程度不足。
- 先進的微小殘留病灶診斷高成本
- 臨床解讀的差異
市場機遇
- 將微小殘留疾病納入臨床試驗終點
- 拓展微小殘留病灶在固態腫瘤的應用領域
- 開發高靈敏度診斷平台
市場挑戰
- 各地區法規的一致性
- 數據解讀的複雜性

第4章商業和市場進入

MRD在製定治療策略中的作用
MRD 作為藥物核准中的替代終點
目前MRD檢測的保險報銷情況
學術機構與地方社區實施的比較
納入臨床指引

第5章：創新與通路的現狀

MRD診斷技術概述
- 利用流式細胞技術檢測微小殘留病灶
- 基於聚合酵素鏈鎖反應（PCR）的微小殘留疾病
- 基於次世代定序（NGS）的微小殘留疾病（MRD）
管道診斷（檢驗平台）
- 適應性生物技術
  - clonoSEQ（基於NGS的微小殘留疾病檢測 - 已獲FDA已經過核准）
  - 適應症：多發性骨髓瘤、急性淋巴性白血病（ALL）、慢性淋巴性白血病（CLL）
  - 管線拓展研究（臨床試驗）
- Guardant Health
  - Guardant Reveal（使用液態生物檢體的微小殘留病灶檢測）
  - 適應症：大腸直腸癌（檢測微小殘留病灶）
  - 持續的臨床檢驗
- Natera
  - Signatera（個人化ctDNA MRD檢測）
  - 適應症：多發性固體癌
  - 臨床試驗的證據
檢測機制
- 基於DNA的檢測
- 免疫表現型分析
- 血液腫瘤DNA（ctDNA）
治療方法的發展趨勢
- 組織內部的MRD
- 透過液態生物檢體微小殘留病灶

第6章當前治療狀況

MRD在治療最佳化中的作用
基於微小殘留病灶的治療策略
已通過核准的MRD 治療方案
- Bristol Myers Squibb
  - Brinatamob（Brincito）- MRD陽性急性淋巴性白血病（ALL）
- AbbVie
  - 維奈托克（Venclexta）－慢性淋巴球白血病（CLL）的微小殘留病灶（MRD）治療
- Janssen Pharmaceuticals
  - Daratumumab（Dalzalex）－多發性骨髓瘤的微小殘留疾病終點
治療反應監測中的微小殘留疾病
復發期微小殘留病灶的預測

第7章：微量殘存疾病的流行病學：市場規模與預測

基於流行病學（歷史資料）的市場規模估算
基於 MRD 檢測實施情況的預測
與診斷普及相關的成長要素
基於情境的預測

第8章：微量殘存疾病流行病學報告的分類

透過技術
- 流式細胞技術
- 基於PCR方法的檢測
- 次世代定序
適應症
- 急性淋巴性白血病
- 急性骨髓性白血病
- 慢性淋巴性白血病
- 多發性骨髓瘤
- 淋巴瘤
依樣本類型
- 骨髓
- 周邊血
最終用戶
- 醫院
- 診斷檢查室
- 學術研究機構

第9章區域分析（區域層級）

北美洲
歐洲
亞太地區
拉丁美洲
中東和非洲

第10章主要國家分析

加拿大
德國
中國
日本
印度

第11章法規與政策概述

美國 - FDA（微小殘留疾病生物標記的合格認證和診斷試劑的批准）
歐洲 - EMA 和 IVDR 框架
日本 - PMDA分子診斷指南
印度—CDSCO關於體外診斷醫療設備的監管現狀
中國 - 國家藥品管理局框架
全球MRD使用指南
臨床實務指引（例如 NCCN、ESMO）
數據標準化和檢驗

第12章競爭格局

MRD診斷提供者的市場佔有率
技術差異（NGS vs. PCR vs.流式細胞技術）
策略聯盟（診斷藥物+製藥）
併購
投資趨勢

第13章：公司簡介

Adaptive Biotechnologies
Natera
Guardant Health
Invivoscribe
F. Hoffmann-La Roche Ltd
Illumina
Thermo Fisher Scientific
Qiagen

第14章：未來展望

固體癌中微小殘留病灶的擴散
作為監管終點的作用日益擴大
與人工智慧和數位診斷的整合
對癌症治療模式的長期影響

第15章：調查方法

調查設計
資料收集（臨床試驗、註冊登記、文獻）
流行病學建模
檢驗框架
先決條件和限制

簡介目錄

Product Code: KSI-008787

The global Minimal Residual Disease (MRD) epidemiology is gaining significant attention as advances in precision oncology and molecular diagnostics transform cancer management. MRD refers to the small number of cancer cells that remain in a patient's body after treatment and are often undetectable using conventional diagnostic methods. Epidemiological analysis of MRD focuses on understanding disease prevalence, incidence, diagnosed patient populations, treatment patterns, relapse rates, and long-term clinical outcomes across hematological malignancies and selected solid tumors. Growing adoption of MRD as a prognostic and predictive biomarker is driving demand for comprehensive epidemiological data to support clinical research, healthcare planning, pharmaceutical development, and commercialization strategies.

The increasing global burden of leukemia, lymphoma, multiple myeloma, and other hematologic cancers continues to expand the need for accurate MRD epidemiological studies. Pharmaceutical companies, diagnostic developers, healthcare providers, and regulatory agencies are increasingly utilizing patient population analyses to guide clinical trial design, evaluate treatment outcomes, identify unmet medical needs, and forecast future demand for MRD testing and targeted therapies. The growing integration of next-generation sequencing (NGS), polymerase chain reaction (PCR), flow cytometry, and liquid biopsy technologies is further enhancing disease monitoring and epidemiological research.

Growing investments in precision medicine, personalized oncology, and biomarker-driven treatment approaches are accelerating the development of comprehensive MRD epidemiology databases across major healthcare markets. Improvements in cancer registries, electronic health records, real-world evidence platforms, and AI-powered data analytics are expected to significantly improve the quality and accuracy of epidemiological forecasting throughout the forecast period.

Market Drivers

Rising Incidence of Hematological Malignancies

The increasing prevalence of leukemia, lymphoma, multiple myeloma, and other blood cancers is driving demand for detailed MRD epidemiology studies to support disease monitoring and treatment planning.
Growing patient populations continue expanding the need for epidemiological analysis.

Increasing Adoption of Precision Medicine

Personalized treatment strategies increasingly rely on MRD assessment for therapy selection, relapse prediction, and long-term disease management.
The shift toward biomarker-driven oncology continues supporting epidemiological research.

Advances in Molecular Diagnostics

Technologies including NGS, PCR, flow cytometry, and liquid biopsy are improving the sensitivity of MRD detection and enabling more accurate patient population assessment.
Technological innovation continues strengthening epidemiological data quality.

Growing Clinical Trial Activity

MRD endpoints are increasingly incorporated into oncology clinical trials to evaluate treatment efficacy and accelerate drug development.
The expansion of biomarker-based clinical research is increasing demand for epidemiological datasets.

Expansion of Real-World Evidence

Healthcare organizations are increasingly utilizing patient registries, electronic medical records, and real-world evidence to improve disease surveillance and epidemiological forecasting.
Advanced analytics continue enhancing healthcare decision-making.

Market Restraints

Limited Standardization of MRD Assessment

Differences in diagnostic methodologies, reporting standards, and clinical practice may affect the consistency of epidemiological data across healthcare systems.
Global harmonization efforts remain ongoing.

High Cost of Advanced Diagnostics

Sophisticated molecular testing platforms require significant investment, limiting widespread access in certain healthcare settings.
Testing accessibility continues to vary across regions.

Limited Data Availability in Emerging Markets

Incomplete cancer registries and variable healthcare reporting systems may reduce the availability of high-quality epidemiological information in developing countries.
Improved healthcare infrastructure is expected to address these limitations over time.

Technology and Segment Insights

By Disease Type

Acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), multiple myeloma, and lymphoma represent the largest segments for MRD epidemiological analysis due to their high reliance on residual disease monitoring.
MRD research is also expanding into selected solid tumors as diagnostic technologies continue to evolve.

By Diagnostic Technology

Next-generation sequencing and PCR-based assays account for a significant share of MRD assessment owing to their high sensitivity and accuracy.
Flow cytometry remains widely utilized for routine clinical monitoring, while liquid biopsy technologies are emerging as promising non-invasive alternatives.

By End User

Pharmaceutical and biotechnology companies represent major users of MRD epidemiology studies for drug development and market forecasting.
Research organizations, hospitals, diagnostic laboratories, academic institutions, and healthcare policymakers also rely extensively on epidemiological data for clinical decision-making and healthcare planning.

Regional Insights

North America represents the largest market for MRD epidemiology analysis due to its advanced healthcare infrastructure, high adoption of precision medicine, extensive cancer registries, and strong clinical research ecosystem. The United States continues to account for the largest diagnosed patient population and the highest level of MRD-related clinical activity.
Europe remains a major market, supported by well-established cancer research networks, expanding molecular diagnostics adoption, and increasing collaboration between healthcare providers and pharmaceutical companies.
Asia Pacific is expected to witness the fastest growth during the forecast period as healthcare infrastructure improves, cancer incidence increases, and investments in precision oncology and molecular diagnostics continue expanding across China, Japan, India, South Korea, and other countries.
Latin America and the Middle East & Africa are gradually strengthening their oncology research capabilities, improving disease surveillance systems, and expanding access to advanced diagnostic technologies.

Competitive and Strategic Outlook

The MRD epidemiology market is supported by collaborations among pharmaceutical companies, diagnostic developers, contract research organizations, academic institutions, healthcare providers, and data analytics companies. Organizations continue investing in real-world evidence generation, AI-powered epidemiological modeling, biomarker research, and integrated patient databases to improve disease forecasting and clinical decision-making.
Strategic initiatives include expanding cancer registries, integrating genomic data with clinical outcomes, developing standardized MRD reporting frameworks, strengthening international research collaborations, and supporting precision medicine initiatives. Increasing adoption of digital health technologies and advanced analytics is expected to further enhance epidemiological insights and improve patient stratification.

Conclusion

The global Minimal Residual Disease epidemiology market is expected to witness sustained growth throughout the forecast period, supported by increasing cancer incidence, expanding adoption of precision oncology, advances in molecular diagnostics, and growing reliance on biomarker-driven treatment strategies. Continuous improvements in real-world evidence generation, genomic technologies, AI-enabled analytics, and healthcare data integration are expected to create significant opportunities for epidemiological research and clinical development. Although challenges related to data standardization, diagnostic accessibility, and regional data availability remain, the expanding role of MRD in personalized cancer management will continue driving demand for comprehensive epidemiological analysis.

Key Benefits of this Report

Insightful Analysis: Comprehensive evaluation of global MRD epidemiology, patient populations, and disease trends.
Competitive Landscape: Assessment of developments in diagnostics, clinical research, and epidemiology-driven drug development.
Market Drivers and Future Trends: Analysis of precision medicine, molecular diagnostics, biomarker adoption, and real-world evidence.
Actionable Recommendations: Support clinical development, commercial planning, investment decisions, and healthcare strategy.
Caters to a Wide Audience: Valuable for pharmaceutical companies, biotechnology firms, diagnostic developers, healthcare providers, research organizations, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Patient population forecasting, epidemiological assessment, clinical trial planning, competitive intelligence, commercialization strategy, investment planning, market opportunity evaluation, healthcare resource planning, and strategic decision-making.

Report Coverage

Historical analysis from 2021 to 2024, base year 2025, and forecast period from 2026 to 2031.
Epidemiology analysis by disease indication, patient population, age group, gender, diagnostic technology, and geography.
Assessment of disease prevalence, incidence, diagnosed cases, treatment patterns, relapse rates, mortality trends, and future patient forecasts.
Analysis of market drivers, restraints, opportunities, clinical research developments, diagnostic innovations, and emerging epidemiological trends.
Regional analysis covering North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

1. Executive Summary

1.1 Epidemiology Snapshot of Minimal Residual Disease (MRD)
1.2 Key Insights Across Hematologic Malignancies
1.3 MRD Testing Adoption Trends
1.4 Key Clinical and Diagnostic Insights
1.5 Analyst Perspective

2. Disease & Epidemiology Analysis

2.1 Overview of Minimal Residual Disease (MRD)
- 2.1.1 Definition and Clinical Significance
- 2.1.2 Role of MRD in Disease Monitoring
2.2 MRD in Hematologic Malignancies
- 2.2.1 Acute Lymphoblastic Leukemia (ALL)
- 2.2.2 Acute Myeloid Leukemia (AML)
- 2.2.3 Chronic Lymphocytic Leukemia (CLL)
- 2.2.4 Multiple Myeloma
- 2.2.5 Non-Hodgkin Lymphoma (NHL)
- 2.2.6 Other Hematologic Disorders
2.3 Global Incidence and Prevalence (Disease-Specific MRD Context)
- 2.3.1 Incidence by Indication
- 2.3.2 Prevalence by Indication
- 2.3.3 Relapse Rates Associated with MRD Positivity
2.4 Patient Stratification and Risk Categorization
- 2.4.1 MRD Positive vs MRD Negative Outcomes
- 2.4.2 Prognostic Value of MRD
2.5 MRD Testing Penetration and Adoption Rates
2.6 Clinical Trial vs Real-World MRD Data Variability

3. Minimal Residual Disease Epidemiology Report Dynamics

3.1 Market Drivers
- 3.1.1 Increasing Use of MRD as a Prognostic Biomarker
- 3.1.2 Growing Adoption of Precision Oncology
- 3.1.3 Expansion of Advanced Molecular Diagnostic Techniques
3.2 Market Restraints
- 3.2.1 Limited Standardization Across MRD Testing Methods
- 3.2.2 High Cost of Advanced MRD Diagnostics
- 3.2.3 Variability in Clinical Interpretation
3.3 Market Opportunities
- 3.3.1 Integration of MRD in Clinical Trial Endpoints
- 3.3.2 Expansion in Solid Tumor MRD Applications
- 3.3.3 Development of High-Sensitivity Diagnostic Platforms
3.4 Market Challenges
- 3.4.1 Regulatory Alignment Across Regions
- 3.4.2 Data Interpretation Complexity

4. Commercial & Market Access

4.1 Role of MRD in Treatment Decision-Making
4.2 MRD as a Surrogate Endpoint in Drug Approval
4.3 Reimbursement Landscape for MRD Testing
4.4 Adoption Across Academic vs Community Settings
4.5 Integration in Clinical Guidelines

5. Innovation & Pipeline Landscape

5.1 Overview of MRD Diagnostic Technologies
- 5.1.1 Flow Cytometry-Based MRD Detection
- 5.1.2 Polymerase Chain Reaction (PCR)-Based MRD
- 5.1.3 Next-Generation Sequencing (NGS)-Based MRD
5.2 Pipeline Diagnostics (Verified Platforms)
- 5.2.1 Adaptive Biotechnologies
  - 5.2.1.1 clonoSEQ (NGS-based MRD assay - FDA authorized)
  - 5.2.1.2 Indications: Multiple Myeloma, ALL, CLL
  - 5.2.1.3 Pipeline Expansion Studies (Clinical Trials)
- 5.2.2 Guardant Health
  - 5.2.2.1 Guardant Reveal (liquid biopsy MRD test)
  - 5.2.2.2 Indications: Colorectal Cancer (MRD detection)
  - 5.2.2.3 Ongoing Clinical Validation
- 5.2.3 Natera
  - 5.2.3.1 Signatera (personalized ctDNA MRD test)
  - 5.2.3.2 Indications: Multiple solid tumors
  - 5.2.3.3 Clinical Trial Evidence
5.3 Mechanism of Detection
- 5.3.1 DNA-based Detection
- 5.3.2 Immunophenotyping
- 5.3.3 Circulating Tumor DNA (ctDNA)
5.4 Modality Trends
- 5.4.1 Tissue-Based MRD
- 5.4.2 Liquid Biopsy MRD

6. Treatment Landscape

6.1 Role of MRD in Therapy Optimization
6.2 MRD-Guided Treatment Strategies
6.3 Approved Therapies with MRD Relevance
- 6.3.1 Bristol Myers Squibb
  - 6.3.1.1 Blinatumomab (Blincyto) - MRD-positive ALL
- 6.3.2 AbbVie
  - 6.3.2.1 Venetoclax (Venclexta) - MRD-driven therapy in CLL
- 6.3.3 Janssen Pharmaceuticals
  - 6.3.3.1 Daratumumab (Darzalex) - MRD endpoints in Multiple Myeloma
6.4 MRD in Treatment Response Monitoring
6.5 MRD in Relapse Prediction

7. Minimal Residual Disease Epidemiology Market Size & Forecast

7.1 Epidemiology-Linked Market Estimation (Historical)
7.2 Forecast Based on MRD Testing Adoption
7.3 Growth Drivers Linked to Diagnostic Penetration
7.4 Scenario-Based Forecasting

8. Minimal Residual Disease Epidemiology Report Segmentation

8.1 By Technology
- 8.1.1 Flow Cytometry
- 8.1.2 PCR-Based Assays
- 8.1.3 Next-Generation Sequencing
8.2 By Indication
- 8.2.1 Acute Lymphoblastic Leukemia
- 8.2.2 Acute Myeloid Leukemia
- 8.2.3 Chronic Lymphocytic Leukemia
- 8.2.4 Multiple Myeloma
- 8.2.5 Lymphomas
8.3 By Sample Type
- 8.3.1 Bone Marrow
- 8.3.2 Peripheral Blood
8.4 By End User
- 8.4.1 Hospitals
- 8.4.2 Diagnostic Laboratories
- 8.4.3 Academic Research Centers

9. Geographical Analysis (Regional Level)

9.1 North America
9.2 Europe
9.3 Asia-Pacific
9.4 Latin America
9.5 Middle East & Africa

10. Key Countries Analysis

10.1 United States
10.2 Canada
10.3 Germany
10.4 United Kingdom
10.5 France
10.6 Italy
10.7 Spain
10.8 China
10.9 Japan
10.10 India
10.11 South Korea
10.12 Australia
10.13 Brazil
10.14 Mexico
10.15 Saudi Arabia
10.16 South Africa

11. Regulatory & Policy Landscape

11.1 United States - FDA (MRD Biomarker Qualification & Diagnostics Approval)
11.2 Europe - EMA & IVDR Framework
11.3 Japan - PMDA Guidelines for Molecular Diagnostics
11.4 India - CDSCO Regulatory Landscape for In Vitro Diagnostics
11.5 China - NMPA Framework
11.6 Global Guidelines on MRD Usage
11.7 Clinical Practice Guidelines (e.g., NCCN, ESMO)
11.8 Data Standardization and Validation

12. Competitive Landscape

12.1 Market Share of MRD Diagnostic Providers
12.2 Technology Differentiation (NGS vs PCR vs Flow Cytometry)
12.3 Strategic Collaborations (Diagnostics + Pharma)
12.4 Mergers and Acquisitions
12.5 Investment Trends

13. Company Profiles

13.1 Adaptive Biotechnologies
- 13.1.1 Approved Product: clonoSEQ (NGS MRD assay)
- 13.1.2 Indications: Multiple Myeloma, ALL, CLL
- 13.1.3 Pipeline Studies and Expansion
13.2 Natera
- 13.2.1 Product: Signatera
- 13.2.2 Indications: Solid tumors
- 13.2.3 Clinical Validation
13.3 Guardant Health
- 13.3.1 Product: Guardant Reveal
- 13.3.2 Indications: Colorectal cancer
- 13.3.3 Pipeline Studies
13.4 Invivoscribe
- 13.4.1 MRD Testing Solutions
- 13.4.2 Indications: Hematologic malignancies
13.5 F. Hoffmann-La Roche Ltd
- 13.5.1 Diagnostic Division (Roche Diagnostics)
- 13.5.2 Oncology Portfolio with MRD endpoints
13.6 Illumina
- 13.6.1 Sequencing Platforms
- 13.6.2 Role in MRD Detection
13.7 Thermo Fisher Scientific
- 13.7.1 PCR & Sequencing Platforms
- 13.7.2 MRD Applications
13.8 Qiagen
- 13.8.1 Molecular Diagnostics Portfolio
- 13.8.2 MRD Testing Support